Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Macular Degeneration

ClinicalTrials.gov lists 1,695 trials for Macular Degeneration or a narrower condition beneath it. National Eye Institute (NEI) has the most among industry and government lead sponsors, with 78.

MeSH D008268 Eye Diseases C11
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 148 Phase 1/2 Phase 1/2 117 Phase 2 Phase 2 255 Phase 2/3 Phase 2/3 40 Phase 3 Phase 3 216 Phase 4 Phase 4 149 Not applicable Not applicable 311 Observational Observational 457 Phase 1 Phase 1 148 Phase 1/2 Phase 1/2 117 Phase 2 Phase 2 255 Phase 2/3 Phase 2/3 40 Phase 3 Phase 3 216 Phase 4 Phase 4 149 Not applicable Not applicable 311 Observational Observational 457

Trials per phase

2 more sections with rows

1,168 of the 1,695 trials are tagged with Macular Degeneration itself; the rest are tagged with a narrower condition beneath it.

Get the Macular Degeneration report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Macular Degeneration trials start? (36)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 3 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access, Unknown)

Top of scale: 96

1990: 2 trials (Phase 3 1, Phase 2 1) 1992: 2 trials (Observational 2) 1993: 1 trials (Phase 3 1) 1994: 1 trials (Observational 1) 1995: 1 trials (Observational 1) 1996: 1 trials (Observational 1) 1997: 1 trials (Phase 1 1) 1998: 4 trials (Observational 2, Not applicable 1, Phase 1/2 1) 1999: 4 trials (Not applicable 1, Phase 3 3) 2000: 7 trials (Observational 5, Phase 3 1, Phase 2 1) 2001: 10 trials (Not applicable 1, Phase 3 1, Phase 2/3 2, Phase 2 2, Phase 1 4) 2002: 13 trials (Observational 1, Not applicable 1, Phase 4 1, Phase 3 4, Phase 2/3 2, Phase 2 2, Phase 1/2 1, Phase 1 1) 2003: 22 trials (Other 1, Observational 5, Not applicable 1, Phase 4 1, Phase 3 4, Phase 2 3, Phase 1/2 2, Phase 1 5) 2004: 31 trials (Observational 2, Not applicable 5, Phase 4 2, Phase 3 8, Phase 2/3 1, Phase 2 7, Phase 1/2 3, Phase 1 3) 2005: 38 trials (Observational 5, Not applicable 6, Phase 4 2, Phase 3 13, Phase 2/3 1, Phase 2 6, Phase 1/2 1, Phase 1 4) 2006: 68 trials (Observational 10, Not applicable 9, Phase 4 7, Phase 3 14, Phase 2/3 4, Phase 2 15, Phase 1/2 4, Phase 1 5) 2007: 87 trials (Observational 14, Not applicable 13, Phase 4 12, Phase 3 17, Phase 2/3 1, Phase 2 18, Phase 1/2 3, Phase 1 9) 2008: 74 trials (Observational 23, Not applicable 7, Phase 4 6, Phase 3 7, Phase 2/3 1, Phase 2 19, Phase 1/2 3, Phase 1 8) 2009: 75 trials (Observational 18, Not applicable 11, Phase 4 4, Phase 3 15, Phase 2/3 1, Phase 2 12, Phase 1/2 8, Phase 1 6) 2010: 62 trials (Observational 13, Not applicable 12, Phase 4 8, Phase 3 2, Phase 2/3 1, Phase 2 12, Phase 1/2 4, Phase 1 10) 2011: 80 trials (Observational 15, Not applicable 16, Phase 4 10, Phase 3 8, Phase 2/3 2, Phase 2 12, Phase 1/2 13, Phase 1 4) 2012: 87 trials (Observational 31, Not applicable 13, Phase 4 11, Phase 3 6, Phase 2/3 2, Phase 2 15, Phase 1/2 6, Phase 1 3) 2013: 69 trials (Observational 19, Not applicable 11, Phase 4 14, Phase 3 12, Phase 2/3 2, Phase 2 6, Phase 1/2 3, Phase 1 2) 2014: 85 trials (Observational 26, Not applicable 13, Phase 4 12, Phase 3 6, Phase 2/3 2, Phase 2 10, Phase 1/2 7, Phase 1 9) 2015: 96 trials (Observational 31, Not applicable 13, Phase 4 9, Phase 3 5, Phase 2/3 1, Phase 2 22, Phase 1/2 11, Phase 1 4) 2016: 60 trials (Observational 13, Not applicable 17, Phase 4 9, Phase 3 7, Phase 2 7, Phase 1/2 2, Phase 1 5) 2017: 51 trials (Observational 19, Not applicable 8, Phase 4 7, Phase 3 3, Phase 2/3 1, Phase 2 8, Phase 1 5) 2018: 73 trials (Observational 16, Not applicable 22, Phase 4 5, Phase 3 9, Phase 2/3 1, Phase 2 9, Phase 1/2 4, Phase 1 7) 2019: 79 trials (Observational 22, Not applicable 17, Phase 4 2, Phase 3 13, Phase 2/3 4, Phase 2 13, Phase 1/2 3, Phase 1 5) 2020: 68 trials (Observational 27, Not applicable 10, Phase 4 1, Phase 3 10, Phase 2/3 1, Phase 2 9, Phase 1/2 4, Phase 1 6) 2021: 80 trials (Observational 23, Not applicable 17, Phase 4 7, Phase 3 13, Phase 2/3 2, Phase 2 7, Phase 1/2 6, Phase 1 5) 2022: 70 trials (Other 1, Observational 22, Not applicable 20, Phase 4 3, Phase 3 8, Phase 2/3 1, Phase 2 9, Phase 1/2 2, Phase 1 4) 2023: 67 trials (Observational 24, Not applicable 15, Phase 4 5, Phase 3 2, Phase 2/3 1, Phase 2 8, Phase 1/2 6, Phase 1 6) 2024: 59 trials (Observational 21, Not applicable 14, Phase 4 4, Phase 3 6, Phase 2/3 3, Phase 2 2, Phase 1/2 6, Phase 1 3) 2025: 81 trials (Observational 30, Not applicable 17, Phase 4 3, Phase 3 6, Phase 2 8, Phase 1/2 6, Phase 1 11)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 69
2025 81
2024 59
2023 67
2022 70
2021 80
2020 68
2019 79
2018 73
2017 51

Showing 10 of 36 earlier years.

Start your 14-day trial Email me all 36 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 87 trials starting in 2026 and about 79 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 117 trials still running at the 2026-10-09 snapshot; registered median of 24 months across 1,095 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Macular Degeneration trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 148
Phase 1/2 117
Phase 2 255
Phase 2/3 40
Phase 3 216
Phase 4 149
Not applicable 311
Observational 457
Expanded access 1
Unknown 1

How many Macular Degeneration trials are recruiting? (10)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 52
Recruiting 155
Enrolling by invitation 14
Active, not recruiting 60
Completed 981

Showing 5 of 10 statuses.

Start your 14-day trial Email me all 10 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Macular Degeneration trials? (11)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Eye Institute (NEI) 78
Novartis Pharmaceuticals 66
Bayer 38
Allergan 37
Genentech, Inc. 25

Showing 5 of 11 sponsors.

Start your 14-day trial Email me all 11 sponsors as a PDF

Which drugs are being tested for Macular Degeneration? (2)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Brolucizumab 19
Abicipar Pegol 9

Interventions as named in the registry (13)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
ranibizumab PRN 226
2.0 aflibercept 129
Bevacizumab 1 55
Dexamethasone/Dexamethasone acetate 31
SHAM injection 25

Showing 5 of 13 interventions.

Start your 14-day trial Email me all 13 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Macular Degeneration trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Invasive cancer of any type 1,617 1
Major cardiovascular event 805 1
Gastrointestinal bleeding 744 1
Myocardial infarction 635 89
Pneumonia 635 127

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Macular Degeneration? (923)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Subretinal Photovoltaic Implant to Restore Vision in Geographic Atrophy Due to AMD. The New England journal of medicine 2026 Yes
Targeted Fluorescence Imaging of Bevacizumab-800CW in Patients with Neovascular Age-Related Macular Degeneration. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2026 Yes
Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE. American journal of ophthalmology 2025 Yes
A Novel Management Challenge in Age-Related Macular Degeneration: Artificial Intelligence and Expert Prediction of Geographic Atrophy. Ophthalmology. Retina 2025 Yes
Validating candidate endpoints for intermediate age-related macular degeneration trials in a multi-centre setting-lessons from the MACUSTAR study. Eye (London, England) 2025 Yes

Showing 5 of 923 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (5)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages